TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...

The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders ...

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common ...

The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...

The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...

A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

Cancer surgery among patients older than 65 years is complex with high morbidity underscoring the need for specialized care at high-quality hospitals.

The LEGEND trial showed a 62% complete response (CR) rate with the non-viral gene therapy at six months in NMIBC patients who ...

Mitchell, who has served as a councilman for 23 years, was diagnosed with bladder cancer in February after previously being ...

An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.

In Gaza, a patient’s suffering does not end at diagnosis. The Israeli blockade has turned obtaining any medical supplies into ...